Prescription medication · Anti-VEGF (Ophthalmic Injection)
aflibercept
Also sold as Eylea. AHZANTIVE treats wet age-related macular degeneration (AMD).
Data updated 2026-05-15
- 29,874
- FDA reportsModerately reported
- Rx
- Availability
aflibercept (Eylea) is a prescription Anti-VEGF (Ophthalmic Injection). AHZANTIVE treats wet age-related macular degeneration (AMD).
AHZANTIVE is a medicine used to treat certain eye problems. It helps to stop blood vessels from growing and leaking in the eye.
Verify with FDA → · CMS NADAC pricing →
What it does
AHZANTIVE treats wet age-related macular degeneration (AMD).
Common side effects
Bleeding in the eye, Eye pain, Clouding of the lens of the eye (cataract)
Key warnings
Injections with AHZANTIVE may cause serious eye infections (endophthalmitis), separation of the retina (retinal detachment), and inflammation of blood vessels in the retina.
The sections below are summarized in plain English from aflibercept's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
AHZANTIVE is a VEGF inhibitor. VEGF is a protein that promotes the growth of new blood vessels. By blocking VEGF, AHZANTIVE helps to reduce the growth of abnormal blood vessels in the eye and decrease leakage.
Side Effects (from patient reports)
Based on 29,874 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for aflibercept, by number of reports
- Death
Death
7,853 reports
- Visual Impairment 2,013
Visual Impairment
2,013 reports
- Blindness 1,459
Blindness
1,459 reports
- Endophthalmitis 1,372
Endophthalmitis
1,372 reports
- Visual Acuity Reduced 1,244
Visual Acuity Reduced
1,244 reports
- Eye Pain 1,181
Eye Pain
1,181 reports
- Vision Blurred 1,161
Vision Blurred
1,161 reports
- Blindness Unilateral 1,068
Blindness Unilateral
1,068 reports
- Blindness Transient 1,028
Blindness Transient
1,028 reports
- Eye Inflammation 970
Eye Inflammation
970 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for aflibercept each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where aflibercept sits
aflibercept has more FDA adverse-event reports than 64% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is aflibercept; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 29,874 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2007–2025.
Total Reports
29,874
Reports Mentioning Death
8,845
29.6% of reports — not proof of cause
Hospitalization Reports
3,872
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | DEATH | 7,853 |
| 2 | VISUAL IMPAIRMENT | 2,013 |
| 4 | BLINDNESS | 1,459 |
| 5 | ENDOPHTHALMITIS | 1,372 |
| 6 | VISUAL ACUITY REDUCED | 1,244 |
| 7 | EYE PAIN | 1,181 |
| 8 | VISION BLURRED | 1,161 |
| 11 | BLINDNESS UNILATERAL | 1,068 |
| 12 | BLINDNESS TRANSIENT | 1,028 |
| 13 | EYE INFLAMMATION | 970 |
| 14 | EYE HAEMORRHAGE | 797 |
| 15 | VITREOUS FLOATERS | 781 |
| 16 | INTRAOCULAR PRESSURE INCREASED | 753 |
| 17 | RETINAL HAEMORRHAGE | 578 |
| 18 | CATARACT | 544 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Injections with AHZANTIVE may cause serious eye infections (endophthalmitis), separation of the retina (retinal detachment), and inflammation of blood vessels in the retina. Tell your doctor right away if you have any signs of these problems. AHZANTIVE may also increase the risk of blood clots that can cause stroke or heart attack.
Common Questions
What if I am allergic to AHZANTIVE?
Can AHZANTIVE be used for both eyes at the same time?
What kind of needle is used to inject AHZANTIVE?
How often will I need AHZANTIVE injections for wet AMD?
How often will I need AHZANTIVE injections for diabetic macular edema?
Can I drive after getting an AHZANTIVE injection?
What should I do if my eye becomes red and painful after the injection?
Will AHZANTIVE cure my eye condition?
Are there any special instructions before the injection?
Can I still wear contact lenses?
What are the common side effects of aflibercept?
What drug class is aflibercept?
What pregnancy or breastfeeding source fields are listed for aflibercept?
Related Medications in Anti-VEGF (Ophthalmic Injection)
Other drugs grouped near aflibercept - same-class peers and common alternatives.
artificial tears
Refresh, Systane
Artificial tears are eye drops that lubricate your eyes.
Compare with aflibercept →
bevacizumab (ophthalmic)
Avastin
Avastin is a medicine that blocks a protein called vascular endothelial growth factor (VEGF).
Compare with aflibercept →
bimatoprost
Lumigan
Bimatoprost eye drops help lower pressure in the eye.
Compare with aflibercept →
brimonidine ophthalmic
Alphagan P
Alphagan P eye drops help lower pressure in the eye.
Compare with aflibercept →
brimonidine/timolol
Combigan
Combigan eye drops contain two medicines that lower pressure in the eye.
Compare with aflibercept →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for aflibercept: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 29,874.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 29.61%.
- voriconazole Δ 0.09 pts · 29,380 reports · Azole Antifungal 29.52%death share
- rifaximin Δ 0.17 pts · 19,891 reports · Non-Systemic Antibiotic (IBS-D) 29.44%death share
- meropenem Δ 0.36 pts · 30,400 reports · Carbapenem Antibiotic 29.97%death share
- buprenorphine Δ 0.94 pts · 90,121 reports · Partial Opioid Agonist 28.67%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on aflibercept
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for aflibercept
The FDA label for aflibercept (sold under brand names such as Eylea) classifies it as a prescription-only medication in the Anti-VEGF (Ophthalmic Injection) class. AHZANTIVE treats wet age-related macular degeneration (AMD). Official labeling lists 6 commonly reported side effects, including Bleeding in the eye, Eye pain, Clouding of the lens of the eye (cataract).
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 29,874 voluntary reports. Interaction data is drawn directly from FDA-approved prescribing information. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: October 27, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages